APRE News and Press, Aprea Therapeutics Inc. From 06/10/20

Investing in biotech stocks focused on experimental oncological therapies is risky enough. What's even more perilous is buying a biotech stock that will make or break on one such candidate alone. Indeed, the probability that an experimental candidate can progress from phase 1 to approval stands ...

Topline data expected by year-end 2020 Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therape...

BOSTON, May 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, President an...

Aprea Therapeutics (NASDAQ: APRE ): Q1 GAAP EPS of -$0.45 beats by $0.11 . More news on: Aprea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BOSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three months ...

Allscripts Healthcare Solutions (NASDAQ: MDRX ) initiated with Outperform rating and $8 (21% upside) price target at RBC. More news on: Allscripts Healthcare Solutions, Inc., Aprea Therapeutics, Inc., Avita Medical Limited, Healthcare stocks news, Stocks on the move, , Read more ...

BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced that it has launched a new, redesigned...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Aprea Therapeutics (NASDAQ: APRE ): Q4 GAAP EPS of -$0.64 misses by $0.24 . Cash and cash equivalents of $130M. Press Release More news on: Aprea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three month...